BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nguyen T, Damiani G, Orenstein L, Hamzavi I, Jemec G. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol 2021;35:50-61. [DOI: 10.1111/jdv.16677] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 23.0] [Reference Citation Analysis]
Number Citing Articles
1 Gulliver W, Alavi A, Wiseman MC, Gooderham MJ, Rao J, Alam MS, Papp KA, Desjardins O, Jean C. Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE study. J Eur Acad Dermatol Venereol 2021. [PMID: 34378812 DOI: 10.1111/jdv.17598] [Reference Citation Analysis]
2 Peña-Rosado A, Riera-Martí N, Expósito-Serrano V, Romaní J. Autoinflammatory keratinitzation diseases (AIKDs. Actas Dermosifiliogr 2021:S0001-7310(21)00208-8. [PMID: 34118208 DOI: 10.1016/j.ad.2021.05.015] [Reference Citation Analysis]
3 Narla S, Lyons AB, Hamzavi IH. The most recent advances in understanding and managing hidradenitis suppurativa. F1000Res 2020;9:F1000 Faculty Rev-1049. [PMID: 32884675 DOI: 10.12688/f1000research.26083.1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
4 Preda-Naumescu A, Ahmed HN, Mayo TT, Yusuf N. Hidradenitis suppurativa: pathogenesis, clinical presentation, epidemiology, and comorbid associations. Int J Dermatol 2021. [PMID: 33890304 DOI: 10.1111/ijd.15579] [Reference Citation Analysis]
5 Ramos-Alejos-Pita C, Arias-Santiago S, Molina-Leyva A. Quality of Life in Cohabitants of Patients with Hidradenitis Suppurativa: A Cross-sectional Study. Int J Environ Res Public Health 2020;17:E6000. [PMID: 32824800 DOI: 10.3390/ijerph17166000] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
6 Seivright J, Thompson AM, Atluri S, Ederle A, Swigert A, Jaros J, Shi VY, Hsiao JL. Hidradenitis suppurativa research from Africa: a bibliometric analysis. Int J Dermatol 2021. [PMID: 33844314 DOI: 10.1111/ijd.15571] [Reference Citation Analysis]
7 Gáspár K, Hunor Gergely L, Jenei B, Wikonkál N, Kinyó Á, Szegedi A, Remenyik É, Kiss N, Jin X, Sárdy M, Beretzky Z, Péntek M, Gulácsi L, Bánvölgyi A, Brodszky V, Rencz F. Resource utilization, work productivity and costs in patients with hidradenitis suppurativa: a cost-of-illness study. Expert Review of Pharmacoeconomics & Outcomes Research. [DOI: 10.1080/14737167.2021.1895753] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Montero-Vilchez T, Diaz-Calvillo P, Rodriguez-Pozo JA, Cuenca-Barrales C, Martinez-Lopez A, Arias-Santiago S, Molina-Leyva A. The Burden of Hidradenitis Suppurativa Signs and Symptoms in Quality of Life: Systematic Review and Meta-Analysis. Int J Environ Res Public Health 2021;18:6709. [PMID: 34206415 DOI: 10.3390/ijerph18136709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Schell SL, Schneider AM, Nelson AM. Yin and Yang: A disrupted skin microbiome and an aberrant host immune response in hidradenitis suppurativa. Exp Dermatol 2021. [PMID: 34018644 DOI: 10.1111/exd.14398] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Johnston DGW, Kirby B, Tobin DJ. Hidradenitis suppurativa: A folliculotropic disease of innate immune barrier dysfunction? Exp Dermatol 2021;30:1554-68. [PMID: 34418166 DOI: 10.1111/exd.14451] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Shaver RL, Jemec GBE, Freese R, Alavi A, Lowes MA, Goldfarb N. A survey of clinicians regarding preferred severity assessment tools for hidradenitis suppurativa. Int J Dermatol 2021;60:e248-51. [PMID: 33179770 DOI: 10.1111/ijd.15295] [Reference Citation Analysis]
12 Montero-Vilchez T, Valenzuela-Amigo A, Cuenca-Barrales C, Arias-Santiago S, Leyva-García A, Molina-Leyva A. The Role of Oral Contraceptive Pills in Hidradenitis Suppurativa: A Cohort Study. Life (Basel) 2021;11:697. [PMID: 34357069 DOI: 10.3390/life11070697] [Reference Citation Analysis]
13 Ramos-Rodríguez D, Garcias-Ladaria J, Serra Soler G, Martín-Santiago A. Hidradenitis suppurativa in a transgender man. Clin Exp Dermatol 2021. [PMID: 33852750 DOI: 10.1111/ced.14680] [Reference Citation Analysis]
14 Gotesman RD, Choi C, Alavi A. Hidradenitis suppurativa in East and Southeast Asian populations: a systematic review and meta-analysis. Int J Dermatol 2021. [PMID: 34075575 DOI: 10.1111/ijd.15671] [Reference Citation Analysis]
15 Frew JW, Singh N, Jiang CS, Vaughan R, Krueger JG. The Impact of Body Mass Index Upon the Efficacy of Adalimumab in Hidradenitis Suppurativa. Front Med (Lausanne) 2021;8:603281. [PMID: 34239882 DOI: 10.3389/fmed.2021.603281] [Reference Citation Analysis]
16 Tran AX, Lefante JJ, Murina A. Risk factors for dissecting cellulitis of the scalp: A case-control study. J Am Acad Dermatol 2021:S0190-9622(21)00635-6. [PMID: 33785386 DOI: 10.1016/j.jaad.2021.03.076] [Reference Citation Analysis]
17 Hanna N, Silverberg OM, Reaume M, Gladman D, Davis MDP, Piguet V, Alavi A. Incidence, prevalence, and predictors of inflammatory arthritis in patients with hidradenitis suppurativa: a systematic review and meta-analysis. Int J Dermatol 2021. [PMID: 34432308 DOI: 10.1111/ijd.15860] [Reference Citation Analysis]
18 Barrea L, Muscogiuri G, Pugliese G, de Alteriis G, Maisto M, Donnarumma M, Tenore GC, Colao A, Fabbrocini G, Savastano S. Association of Trimethylamine N-Oxide (TMAO) with the Clinical Severity of Hidradenitis Suppurativa (Acne Inversa). Nutrients 2021;13:1997. [PMID: 34200594 DOI: 10.3390/nu13061997] [Reference Citation Analysis]